Fundraising Fox
ReadCoor
Cambridge, US · Founded 2016 · Delaware corporation · 2,439 employees on LinkedIn · 6 known investors
Find your way into ReadCoor
Sign up to see every warm intro you have to ReadCoor
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ReadCoor team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Readcoor developed an in situ spatial transcriptomics platform using padlock probe rolling circle amplification chemistry to detect and map RNA transcripts across tissue sections, now offered as the Xenium In Situ platform. It serves researchers analyzing gene expression at subcellular resolution, including in FFPE and degraded samples.
Founders & leadership
ReadCoor was founded in 2016 by Evan Daugharthy.
Board
Investors · 6
How we know: Decheng Capital's portfolio page · globalventuring.com · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: funding news · globalventuring.com · Not right? Tell us
Also in the syndicate · 1
Reported raises · per SEC filings
Form D private placements$52.4M disclosed across 3 rounds · 2016–2019
▶$26.8MraisedOct 2019 · 4 investors · Other Health CareRule 506(b)
- Thomas GroganDirector
- Victor TongDirector
- Richard TerryExecutive Officer, Director
- Offering amount
- $30.1M
- Amount sold
- $26.8M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$2.6MraisedJul 2019 · 1 investors · Other Health CareRule 506(b)
- Yuh-Geng TsayDirector
- Thomas GroganDirector
- Victor TongDirector
- Richard TerryExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $2.6M
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$23MraisedSep 2016 · 5 investors · Other Health CareRule 506(b)
- Yuh-Geng TsayDirector
- Victor TongDirector
- Richard TerryExecutive Officer, Director
- Shawn MarcellExecutive Officer, Director
- Offering amount
- $23M
- Amount sold
- $23M
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does ReadCoor do?
- Readcoor developed an in situ spatial transcriptomics platform using padlock probe rolling circle amplification chemistry to detect and map RNA transcripts across tissue sections, now offered as the Xenium In Situ platform. It serves researchers analyzing gene expression at subcellular resolution, including in FFPE and degraded samples.
- Who founded ReadCoor?
- ReadCoor was founded by Evan Daugharthy in 2016.
- Who are ReadCoor's investors?
- ReadCoor's investors include Decheng Capital, LAV, Lilly Asia Ventures, Lilly Ventures, Vivo Capital.
- How much funding has ReadCoor raised?
- ReadCoor has disclosed $52.4M raised across 3 rounds.
- Where is ReadCoor headquartered?
- ReadCoor is headquartered in Cambridge, US.